2023 International Congress Archives - Page 175 of 186

iCARE-PD: a multinational multicenter feasibility study of Integrated Care Networks in Parkinson disease

D. Dash, D. Grimes, J. Saade, R. Bouça, J. Ferreira, E. Ruzicka, A. Sanchez-Ferro, T. Lynch, M. van Munster, D. Pedrosa, M. Fabbri, O. Rascol, T. Mestre ()
Identification of a Metabolic Brain Pattern Specific to Corticobasal Degeneration and Its Utility in Differential Diagnosis

T. Rus, J. Jamšek, M. Perovnik, M. Trošt (Ljubljana, Slovenia)
Identification of atlastin genetic modifiers in a Hereditary Spastic Paraplegia model in Drosophila

P. Olguin, N. Candia, A. Ibacache, I. Medina-Yañez, G. Olivares, M. Ramirez, F. Vega-Macaya, A. Couve, J. Sierralta (Santiago, Chile)
Identification of potential oxidative biomarkers in saliva of Parkinson’s disease patients

J. Rungta, A. Roy, S. Choudhury, S. Ansari, P. Chatterjee, R. Khatun, R. Pramanik, S. Dey, H. Kumar (Kolkata, India)
Identification of pre-frailty in the elderly through serum metabolomics and its impact on Parkinson’s disease phenotype

A. Imarisio, M. Avenali, G. Buongarzone, M. Picascia, T. Nuzzo, C. Gasparri, F. Errico, C. Marino, M. Grimaldi, MC. Monti, A. Filosa, M. Rondanelli, C. Pacchetti, AM. D'Ursi, A. Usiello, EM. Valente (Pavia, Italy)
Identification of reproducible metabolites for Parkinson’s Disease diagnosis using clinical data and computational modelling

X. Luo, YJ. Liu, A. Balck, C. Klein, R. Fleming (Galway, Ireland)
Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline

B. Ugbedeojo, P. Adoyi, A. Abah, O. Onimisi, S. Musa, A. Omoniyi (Zaria, Nigeria)
Identification of ZYIL1, a novel NLR family pyrin domain containing 3 protein inhibitor: a potential disease modifier in Parkinson’s disorder

A. Chatterjee (Ahmedabad, India)
Identifying a path to improve diagnostic delay and access to care for PSP, CBS, and MSA

M. Bruno, F. Ali, M. Dale, M. Schmidt, M. Comeau, C. Spears, J. Shurer (Honolulu, USA)
Identifying delirium in Parkinson’s: evaluation of existing tools and measures

R. Lawson, S. Richardson, F. Gerakios, G. Bate (Newcastle upon Tyne, United Kingdom)
Identifying neural biomarkers of motivated behavior in Parkinson’s disease using sensing-capable DBS devices

N. Provenza, S. Rajesh, N. Diab, S. Reddy, B. Lamichhane, A. Sabharwal, J. Herron, Y. Gazes, C. Le Heron, S. Sheth, N. Vanegas-Arroyave (Houston, USA)
Identifying prodromal NMS in a population-based recruitment strategy: Kassel data of Healthy Brain Ageing

S. Schade, C. Vega Moreno, C. Horlings, A. Garrido, T. Marques, P. Mahlknecht, E. Bryan, C. Gomes, C. Pauly, S. Ghosh, K. Rege, R. Rawal, T. Wicke, E. Lang, S. Schnell, V. Satagopam, K. Seppi, M. Marti, E. Tolosa, W. Poewe, R. Krüger, C. Trenkwalder, B. Mollenhauer (Kassel, Germany)
Idiopathic Intracranial Hypertension as the presenting symptom in Wilson’s Disease: how is it possible?

V. Mesquita, F. Rolim, A. Gomes, R. Carvalho, P. Matos, A. Marinho, N. Frota, F. Carvalho (Fortaleza, Brazil)
Image-guided programing in useful in DBS for Parkinson’s disease

S. Marmol, J. Moll, H. Bullock, I. Haq, J. Jagid, C. Luca (Miami, USA)
Imaging the noradrenergic system in Parkinson’s disease: A [11C]Yohimbine PET and neuromelanin MRI study

C. Laurencin, S. Lancelot, M. Huddlestone, S. Brosse, I. Merida, N. Costes, J. Redouté, S. Thobois, P. Boulinguez, B. Ballanger (Lyon, France)
Impact of culture on Impulse control disorders and correlation with levodopa-induced dyskinesia in Parkinson’s disease in Egypt .

AHM. Mahmoud (Tahta, Egypt)
Impact of Decreased Cognitive Function on the Risk of Falling in the Elderly

R. Nindela, N. Sitohang, S. Marisdina (Palembang, Indonesia)
Impact of deep brain stimulation of the subthalamic nuclei on non-motor symptoms in Parkinson’s disease: a monocentric prospective study with a 12-month follow-up

V. Leclercq, V. Donckels, E. Hanon, S. Dethy (Sint-Pieters-Leeuw, Belgium)
Impact of dopamine replacement therapy on shame in Parkinson’s disease patients

S. Catalano Chiuvé, D. Benis, A. Zulet, P. Krack, V. Fleury (Geneva, Switzerland)
Impact of dual tasking and sensory manipulation on balance in Fragile X-associated tremor/ataxia syndrome (FXTAS) and potential prodromal postural sway deficits in asymptomatic FMR1 premutation carriers

E. Timm, N. Cao, N. Purcell, B. Ouyang, Y. Liu, D. Hall, J. O'Keefe (Chicago, USA)
Impact of endpoint selection on sample size calculations for disease-modifying clinical trials in Parkinson’s disease patients with GBA1 mutations

M. Fonseca, G. Castilla-Fernández, J. Liu, J. Holenz, N. Mendonça, D. Simon (Porto, Portugal)
Impact of globus pallidus interna deep brain stimulation on REM sleep behavior disorder in Parkinson’s disease

A. Mahes, A. Wiltshire, S. Wang, J. Zuzuarregui (San Francisco, USA)
Impact of Image-Guided Programming (IGP) in Bilateral STN Deep Brain Stimulation on Programming Time and Setting Outcomes

J. Aldred, T. Zesiewicz, M. Okun, J. Ramirez-Castaneda, L. Verhagen-Mehtman, C. Luca, R. Ramdhani, J. Durphy, Y. Bezchlibnyk, J. Carlson, K. Foote, S. Sani, A. Papanastassiou, J. Jagid, D. Weintraub, J. Pilitsis, B. Reese, L. Chen, R. Jain (Spokane, USA)
Impact of istradefylline on the onset of dyskinesia in Parkinson’s Disease patients with wearing off: a randomized controlled study (ODYSSEI)

Y. Tsuboi, T. Hasegawa, Y. Shimo, S. Kaneko, M. Tomiyama, K. Kashihara, S. Chiu, T. Yamaguchi (Fukuoka, Japan)
Impact of non-motor fluctuations on QOL in patients with Parkinson’s disease

A. Kakimoto, M. Kawazoe, K. Kurihara, T. Mishima, Y. Tuboi (Fukuoka, Japan)
Impact of non-pharmacological strategies on progression in Parkinson’s Disease and Cognitive Impairment.

MAG. Medrano-Delgado, DR. Aguila-Godinez, MF. Ruiz-Mafud, LG. Lira-Juárez, EC. Santiago Delacruz, A. Domínguez-García, AJ. Hernández-Medrano, AY. Regalado-Mustafá, MF. Medina-Pérez, G. Hernandez-Armesto, K. Talavera-Laguna, A. Herrera-Ruiz, J. García-Hernández, DP. Romero-Terán, A. Alcocer-Salas, G. Cerda-Hernández, A. Abundes-Corona, M. Rodríguez-Violante, A. Cervantes-Arriaga (Ciudad de Mexico, Mexico)
Impact of orthostatic hypotension with sleep disturbance on cognition

A. Ovchynnykova, E. Trufanov (Kyiv, Ukraine)
Impact of the COVID-19 pandemic in the long-term efficacy of botulinum toxin treatment

F. Barros, C. Nunes, F. Magalhães, A. Mestre, C. Machado, D. Carneiro (Coimbra, Portugal)
Impact of the COVID-19 pandemic on DBS accessibility: a single center experience

F. Sarmento, S. Aghili-Mehrizi, T. de Araujo, J. Wong (Gainesville, USA)
Impact of the severity of Parkinson’s disease on skin elasticity

SY. You, HJ. Park (Daegu, Republic of Korea)
Impact of vitamin supplements intake on non-motor fluctuations measured by (NoMoFA) in people living with Parkinson’s disease.

M. Ruiz Mafud, A. Hernández Medrano, D. Aguila Godinez, A. Herrera Ruiz, D. Romero Teran, M. Medrano Delgado, M. Rodriguez Violante, A. Cervantes Arriaga, L. Lira Juarez, A. Abundes Corona, G. Hernandez Armesto, E. Santiago Cruz, A. Dominguez Garcia, A. Regalado Mustafá, G. Cerda Hernandez, K. Talavera Lagunas (Cuidad de México, Mexico)
Impacts of mutations in Parkinson’s disease-related genes on telomere maintenance

YH. Chen, CH. Lin, CK. Tseng (Taipei, Taiwan)
Impaired CaMKII/ERK activation in mouse mutant LRRK2 R1441G fibroblasts was associated with reduced mitochondrial calcium store and efflux in response to depolarization stress

E. Chang, Y. Malki, Z. Choi, H. Liu, S. Zhang, S. Pang, M. Kung, D. Ramsden, S. Ho, P. Ho (Hong Kong, Hong Kong)
Impaired lysophagy function exacerbates propagation of α-synuclein aggregation

K. Kakuda, K. Ikenaka, C. Aguirre, C. Choong, J. Doi, Y. Kimura, H. Mochizuki (Osaka, Japan)
Impaired mitochondrial respiration as a peripheral tissue biomarker for stratifying idiopathic Parkinson’s disease

S. Kverneng, K. Stige, H. Berven, S. Mostafavi, M. Brischigliaro, B. Brakedal, G. Skeie, G. Nido, I. Flønes, E. Fernandez-Vizarra, C. Dölle, C. Tzoulis (Bergen, Norway)
Impaired Mitophagy and Mitochondrial-energetics in Parkinson’s disease: A Novel Therapeutic Strategy of Re-tasking Felodipine

A. Roy, S. Choudhury, R. Banerjee, A. Costa, P. Sheshadri, M. Duchen, S. Dey, H. Kumar (Kolkata, India)
Impaired Nt-acetylation and the Golgi, a new disease mechanism leading to autosomal recessive primary familial brain calcifications

V. Chelban, H. Aksnes, L. Lamonica, R. Maroofian, L. Seabra, P. Devic, J. Vandrovcova, D. Murphy, A. Pagnamenta, N. Wood, R. Horvath, A. Ernst, J. Rothman, M. Mcentagart, Y. Crow, G. Nicolas, T. Arnesen, H. Houlden (London, United Kingdom)
Impaired structural connectivity in Parkinson’s disease with probable RBD

J. Oltra, I. Roura, A. Campabadal, C. Uribe, J. Pardo, MJ. Martí, Y. Compta, F. Valldeoriola, N. Bargallo, A. Iranzo, C. Junque, B. Segura (Barcelona, Spain)
Impairment of SHH signaling in PD LRRK2 I1371V iPSC derived floor plate cells contribute to ontogenic origin of lower dopaminergic-neuron yield

I. Datta, S. Jagtap, C. Potdar, K. Singh (Bengaluru, India)
Implementation and effects of telehealth exercise therapy on satisfaction and Mobility In persons with Parkinson’s.

F. Yadolahi, N. Hosseini (tehran, Islamic Republic of Iran)
Improved Tremor Response to Focused Ultrasound Thalamotomy

J. Holcomb, R. Chopra, F. Feltrin, M. Elkurd, R. El-Nazer, L. Mckenzie, P. O’Suillebhain, J. Maldjian, W. Dauer, B. Shah (Dallas, USA)
Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson’s disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion

A. Antonini, B. Bergmans, D. Kern, P. Odin, L. Bergmann, R. Gupta, J. Homola, M. Shah, J. Zamudio, D. Standaert (Padova, Italy)
Improvement in spasticity-associated dressing- and hygiene-related disability in adults following treatment with incobotulinumtoxinA: a pooled analysis

F. Molteni, J. Wissel, K. Fheodoroff, M. Munin, A. Patel, M. Althaus, G. Comes, A. Dekundy, I. Pulte, A. Scheschonka, M. Vacchelli, A. Santamato (Costa Masnaga, Italy)
Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials

K. Chaudhuri, M. Bouchard, E. Freire-Alvarez, R. Pahwa, L. Bergmann, R. Gupta, P. Kukreja, M. Shah, S. Isaacson (London, United Kingdom)
Improvement of short-term satisfaction with life and treatment in Parkinson´s disease after subthalamic stimulation

A. Sauerbier, P. Bachon, L. Ambrosio, P. Loehrer, A. Rizos, S. Jost, A. Gronostay, G. Fink, K. Ashkan, C. Nimsky, V. Visser-Vandewalle, K. Ray Chaudhuri, L. Timmermann, P. Martinez-Martin, H. Dafsari (Köln, Germany)
Improvements in Parkinson’s disease motor complications after treatment with opicapone: results from the OPTI-ON study

C. Kilbane, R. Drake, O. Klepitskaya, M. Serbin, E. Jen, S. Rattana, J. Trotter, G. Liang (Cleveland, USA)
Improving inpatient medication management in hospitalized Parkinson’s patients

R. Schell, J. Stroh, F. Phibbs, A. Depp, C. Eastburn, A. Boudreaux (Not Hispanic/Latino/Latina/Latinx, USA)
Impulse Control Disorder and medication management in Patients with Early-Onset Parkinson’s Disease

J. Jacobson, K. Ghoniem, A. Mullan, P. Turcano, C. Stang, E. Camerucci, C. Piat, J. Bower, R. Savica (Rochester, USA)
Impulse control disorder related to dopaminergic therapy in progressive supranuclear palsy

T. Thammongkolchai, P. Termsarasab (Bangkok, Thailand)
In silico electrophysiology study reveals the modulating role of calcium channel on Subthalamic nucleus neuronal cells towards Parkinson’s disease

G. Kuanar, C. Mahapatra (Cuttack, India)
In vitro α–synuclein aggregation and propagation model

F. Kapucu, I. Tujula, O. Kulta, L. Sukki, V. Vuolanto, A. Vinogradov, P. Kallio, S. Narkilahti (Tampere, Finland)
In vivo assessment of striatal compartments in patients with idiopathic upper limb dystonia

AJM. Paulo, J. Waugh, JPQ. de Paiva, JR. Sato, DD. de Faria, V. Borges, SMA. Silva, HB. Ferraz, PMC. Aguiar (São Paulo, Brazil)
In vivo positive amyloid PET in a patient with PDD, always reliable?

S. Enriquez, D. Samaniego, C. Lorenzo-Bosquet, E. Martinez-Saez, A. Garcia-Serra, B. Garcé, S. Belmonte, J. Hernández-Vara (Barcelona, Spain)
In vivo proteomic investigation of deeply phenotyped parkinsonian syndromes for biomarkers of differential diagnosis

S. Katzdobler, A. Bernhardt, G. Nübling, C. Palleis, U. Fietzek, E. Weidinger, M. Brendel, G. Höglinger, J. Levin (Munich, Germany)
Incidence and Predictors of Axial Postural Abnormalities in Parkinson disease: data from the PPMI cohort

CA. Artusi, C. Campisi, C. Ledda, K. Tsukita, D. Rinaldi, L. Lopiano, M. Fabbri (Torino, Italy)
Incidence of childhood trauma in patients with functional movement disorder and its impact on motor symptoms severity

L. Nováková, T. Serranová, P. Sojka, D. Voženílek (Praha, Czech Republic)
Incidence of dysphagia and comorbidities in patients with cervical dystonia, analyzed by botulinum neurotoxin treatment exposure

M. Sadeghi, A. Ukah, E. Yue, K. Becker Ifantides, N. Huang, J. Lee, R. Barbano (Irvine, USA)
Incidence of orthostatic hypotension in Parkinson´s disease patients starting antiparkinsonian treatment

C. Borrue, P. Couto (San Sebastian delosReyes, Spain)
Incidence of Parkinson’s disease and modifiable risk factors in Korean population: A longitudinal follow-up study of a nationwide cohort

SJ. Chung, SH. Kang, S-J. Moon, M. Kang, GJ. Cho, S-B. Koh (Goyang, Republic of Korea)
IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study: 4-year interim results

B. Bergmans, N. Winter, V. Schotte, N. Sys, L. Delameilleure, E. van Massenhove, H. Couckuyt, M. van Zandijcke (Bruges, Belgium)
Increased alpha power in basal ganglia and thalamus following levodopa administration in a dystonic young adult

J. Nataraj, J. Maclean, SA. Seyyed Mousavi, J. Olaya, M. Liker, T. Sanger (Irvine, USA)
Increased free water in the putamen in idiopathic REM sleep behaviour disorder

D. Zhang, L. Zhou, J. Liu, T. Wu (Beijing, China)
Increased incidence of Functional movement disorders during COVID-19 pandemic

A. Cherian, D. Kalikavil Puthanveedu, N. Paramasivan, K. S (Thiruvananthapuram, India)
Increased MD and decreased FA reflect cognitive impairment in PSP

S. Kannenberg, AC. Hausmann, A. Schnitzler, CJ. Hartmann, C. Rubbert, J. Caspers (Düsseldorf, Germany)
Incremental Hospitalizations and Associated Costs of Co-existing Dementia in Patients with Parkinson’s Disease Psychosis: An analysis of US Medicare Beneficiaries

N. Rashid, K. Rajagopalan, D. Gopal, D. Doshi (San Diego, USA)
Indirect treatment comparison of valbenazine with deutetrabenazine for improvement in total maximal chorea score in Huntington disease

R. Mehanna, E. Furr Stimming, D. Haubenberger, O. Klepitskaya, S. Aggarwal, S. Kumar, O. Topaloglu, J. Goldstein, E. Kayson, M. Serbin (Houston, USA)
Individual-specific brain functional connectivity mapping of therapeutic response in task-specific focal dystonia

E. Gordon, K. Matthews, A. Meyer, S. Norris (St. Louis, USA)
Inferring Rigidity Scores in MDS-UPDRS Motor Assessment from Other Items

F. Duque Quiceno, Y. Dushin, G. Sarapata, S. Komarov, A. Matveev, J. O'Keeffe (London, United Kingdom)
Influence of Cognitive Function on Obstacle-Crossing Performance in People with Parkinson’s Disease: A Cross-Sectional Study

HH. Hsu, RY. Wang, NC. Yeh, PL. Wong, CW. Hung (Taipei, Taiwan)
Influence of square-stepping exercise on brain activation in older adults with cognitive frailty

YH. Wang, RY. Wang, YR. Yang (Taipei, Taiwan)
Informing people with Parkinson’s disease of their gene variant status: PD GENEration, a North American observational and registry study

L. Cook, J. Verbrugge, T. Schwantes-An, T. Foroud, A. Hall, K. Marder, I. Mata, N. Mencacci, M. Nance, M. Schwarzschild, T. Simuni, A-M. Wills, S. Rao, K. Ghosh Galvelis, A. Naito, J. Beck, R. Alcalay (Indianapolis, USA)
Inhibition of LRRK2 kinase activity promotes glucocerebrosidase transport to the lysosomes in primary monocyte-derived macrophages from patients with GBA-associated Parkinson’s disease

K. Basharova, A. Bezrukova, A. Izyumchenko, G. Baydakova, I. Miliukhina, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)
Inhibitory and facilitatory alterations in prodromal and de novo Parkinson’s disease

A. Rizzardi, A. Benussi, A. Pilotto, C. Tirloni, V. Cantoni, C. Zatti, A. Galli, B. Borroni, A. Padovani (Brescia, Italy)
Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson’s disease

J. Szász, V. Constantin, K. Orban-Kiss, S. Bataga, L. Bancu, R. Neagoe, J. Szederjesi, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari (TARGU MURES, Romania)
Initial clinical experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson´s disease in Croatia

P. Bago Rožanković, S. Lasić, F. Borovečki, S. Telarović, R. Perković, V. Vuletić, O. Perković, V. Rački, S. Tomić (Zagreb, Croatia)
Initial triggering in tibial group and subsequent slow spread of myoclonus from brain stem to eye-balls in Subacute Sclerosing Pan Encephalitis

A. Das, J. George, A. Garg, A. Srivastava (Delhi, India)
Innovating Clinical Trial Design to Accelerate Assessment of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Initiative

G. Mills, R. Chapman, S. Collins, R. Ellis-Doyle, C. Gonzalez-Robles, M. Zeissler, O. Bandmann, R. Barker, J. Carpenter, J. Chataway, J. Duffen, S. Gandhi, K. Mcfarthing, S. Mullin, A. Schapira, A. Schrag, C. Carroll, T. Foltynie (London, United Kingdom)
Instability after MRIg-FUS thalamotomy: why does it appear?

A. Fernandez Revuelta, C. Ribacoba Díaz, J. Porta Etessam, C. Pérez García, M. Yus, E. López Valdés, R. García-Ramos (Madrid, Spain)
Insular dopamine deficits in prodromal α-synucleinopathies

A. Galli, A. Pilotto, C. Zatti, F. Placidi, F. Izzi, E. Premi, A. Rizzardi, M. Catania, A. Lupini, L. Purin, M. Pasolini, N. Mercuri, A. Chiaravalloti, M. Fernandes, C. Calvello, B. Paghera, D. Berg, A. Padovani, C. Liguori (Brescia, Italy)
Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.

P. Odin, T. Kimber, B. Bergmans, E. Freire-Alvarez, F. Gandor, S. Isaacson, S. Dhanani, R. Hauser, M. O'Meara, A. Jeong, J. Jia, R. Gupta, L. Bergmann, M. Shah, L. Harmer, S. Talapala, J. Aldred (Lund, Sweden)
Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)

L. Guedes, D. Hilt, M. Fonseca, I. Peixoto, H. Gama (Coronado, Portugal)
Integrating care coordination into telemedicine services provides a better patient experience than care coordination alone: Insights from a national neurodegenerative disease telemedicine program

J. Hatcher-Martin, C. Byrne, E. Anderson (Chicago, USA)
Integrative analysis of fecal metabolomics and metagenomics for Parkinson’s disease

Y. Qian, S. Xu, X. He, Y. Lai, Y. Zhang, C. Mo, P. Ai, X. Yang, Q. Xiao (Shanghai, China)
Integrative brain states facilitate the expression of Parkinson’s tremor

MF. Dirkx, M. Shine, RC. Helmich (Nijmegen, Netherlands)
Intercultural differences in patient and clinician perceptions of MDS-UPDRS in Parkinson’s disease

V. Kaasinen, S. Luo, P. Martinez-Martin, C. Goetz, G. Stebbins (Turku, Finland)
Internal tremor in Parkinson disease and essential tremor: a new glance at a common symptom

A. Fonseca, M. Lima, C. Duque, V. Carvalho, M. Calejo (Matosinhos, Portugal)
Intra operative mer with stn-dbs in local and globally anesthetized Parkinson`s analysis: a melancholic nostalgy group study

L. Neerati, V. Venkateshwara, G. Rama Raju (Hyderabad, India)
Intrarater and interrater reliability of the 3 meter backward walk test in individuals with Parkinson disease.

A. Boddy, K. Barta, L. Perry, M. Flores, K. Sawyer, A. Campbell (St Augustine, USA)
Introducing the molecular subtyping of Progressive Supranuclear Palsy: a proof of concept

I. Martinez-Valbuena, S. Lee, E. Santamaria, J. Fernandez-Irigoyen, B. Couto, N. Reyes, H. Tanaka, S. Forrest, A. Kim, H. Qamar, J. Li, A. Karakani, K. Senkevich, E. Rogaeva, N. Visanji, A. Lang, G. Kovacs (Toronto, Canada)
Introduction of a Parkinson’s Disease Virtual Ward Round

K. Ramsay (Sutton-in-Ashfield, United Kingdom)
Intronic FGF14 GAA repeat expansions are a common cause of ataxia syndromes with neuropathy and bilateral vestibulopathy

D. Pellerin, C. Wilke, A. Traschütz, S. Nagy, R. Currò, M-J. Dicaire, H. Garcia-Moreno, M. Anheim, T. Wirth, J. Faber, D. Timmann, C. Depienne, D. Rujescu, J. Gazulla, M. Reilly, P. Giunti, B. Brais, H. Houlden, L. Schöls, M. Strupp, A. Cortese, M. Synofzik (Montreal, Canada)
Investigate the association of MAPT haplotype and neuroanatomical structure and its influence on the risk of Parkinson’s disease

E. Yu, C. Tremblay, A. Vo, Y. Sosero, Z. Gan-Or, A. Dagher, L. Liu ()
Investigating Digital Biomarkers in Parkinson’s Disease

C. Louis, R. Shon, E. Shah, S. Isfahani (Fullerton, USA)
Investigating factors contributing to clinical trial recruitment in Parkinson’s Disease within the Black community

J. Adrissi, C. Onwumere, D. Dominguez, M. Lyleroehr, E. Gray, K. Williams, E. Zivin, D. Larson (Los Angeles, USA)
Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease

I. Trezzi, M. Regoni, M. Magni, M. Schröter, A. Buccino, D. Lopez, G. Faustini, L. Murro, F. Biella, E. Frattini, R. Silipigni, M. Passafaro, A. Bellucci, M. Bortolozzi, J. Sassone, A. Di Fonzo (Milan, Italy)
Investigation of superficial brain stimulation (SBS) in Parkinsonian rats as a non-invasive alternative treatment for patients with movement disorders

G. Weistroffer, J. Blagg, M. Tashli, R. Hadimani, D. Kumbhare, M. Baron (Richmond, USA)
Investigation of usefulness of new MSA diagnostic criteria

M. Tarisawa, M. Matsushima, A. Kudo, K. Sakushima, Y. Kanatani, N. Nishimoto, J. Sawada, T. Matsuoka, S. Hisahara, H. Uesugi, N. Minami, K. Sako, A. Takei, A. Tamakoshi, N. Sato, H. Sasaki, I. Yabe (Sapporo, Japan)
IP-RT-QuIC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with syncleinopathy

A. Okuzumi, T. Hatano, G. Matsumoto, N. Hattori (Tokyo, Japan)
IParkours : Role of the advanced practice nurse (APN) in the support/follow-up of parkinsonian patients.

JT. Thezenas (Yerres, France)
Ipilimumab/Nivolumab-related orthostatic myoclonus in a patient with metastatic melanoma

B. Green, W. Tse (New York, USA)
Iron deposition and volume change of deep grey matter nuclei in PARK14 by Quantitative Susceptibility Mapping

C. Chen, X. Liu, F. Liu, Y. Sun, J. Wang (Shanghai, China)
Is a Parkinson’s Sialorrhoea service effective?

C. Williams, J. Adenwalla, B. Mohamed, C. Marquis, C. Thomas, R. Lewis-Morton (cardiff, United Kingdom)
Is an integrated Parkinson’s Dementia Service the way forward?

A. Rafeeq, C. Thomas, B. Mohamed, J. Adenwalla, S. Page, R. Lewis-Morton, S. Mahon, T. Williams (Cardiff, United Kingdom)
Is cognitive function related to daily life gait and turning in people with Parkinson’s disease?

M. Mancini, P. Burgos, P. Carlson-Kuhta, C. Silva-Batista, A. Ragothaman, V. Shah, F. Horak (Portland, USA)
Is it safe to switch from constant voltage to constant current with a mixed Internal Pulse Generator in deep brain stimulation

G. Ozturk Ozluk (Istanbul, Turkey)
Is STN a good target for decrease off period by DBS, Gpi – for reduction of dyskinesia in PD patients?

A. Buniak, V. Alexeyevets, S. Likhachev, V. Bayarchyk (Minsk, Belarus)
Is there a common structural network for stimulation-induced dysarthria in subthalamic and thalamic deep brain stimulation?

JN. Petry-Schmelzer, H. Jergas, T. Thies, JC. Baldermann, V. Visser-Vandewalle, TA. Dembek, MT. Barbe (Cologne, Germany)
Is there impairment in neuromuscular trunk control in Parkinson disease when compared to healthy elderly?

H A. Araújo, A. Melanda, R. da Silva, S. Smaili (Londrina, Brazil)
Is working memory training success in Parkinson’s disease determined by cortical thickness and white matter lesions?

K. Giehl, H. Theis, A. Ophey, J. Hammes, P. Reker, C. Eggers, E. Kalbe, T. van Eimeren (Cologne, Germany)
Isolated vocal tremor: a case series

J. Bundy, Y. Kianirad (Chicago, USA)
Isolated ZIC-4 antibody associated cerebellar dysfunction triggered by Tuberculosis

S. Garg, K. Shetty, S. Agrawal (Bengaluru, India)
Isolation of L1CAM-extracellular vesicles reveals signs of insulin resistance in Parkinson’s disease

I. Markaki, W. Paslawski, T. Ntetsika, P. Svenningsson (Stockholm, Sweden)
Istradefylline effect on Parkinson’s Disease Tremor, Motor symptoms and non-Motor symptoms.

K. Chandrakumar, B. Wilmarth, B. Nagle, G. Di Maria, O. Gonul, L. Lovelace, E. Waldon, K. Getchell, Y. Torres-Yaghi, F. Pagan (Washington, USA)
Istradefylline therapy for PD plus oromandibular dystonia

NAO. Kanzato, SAT. Mochizuki (Haearu-cho, Okinawa, Japan)